Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)
NCT: NCT04585477 · SUSPENDED
Brief Summary
In this study circulating tumor DNA (ctDNA) blood testing is used to detect the residual blood cancer. If residual cancer using this blood test is detected there may be at higher risk of having the cancer return. The study is going to test whether or not the number of circulating cancer cells detected in the blood can be reduced by administration durvalumab after the standard treatment if you are tested positive for the residual cancer.
Frequently Asked Questions
What is Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)?
Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E) is a clinical trial registered under NCT04585477. Current status: SUSPENDED.
What is the status of NCT04585477?
The current status of NCT04585477 (Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)) is: SUSPENDED.
When did Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E) start?
Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E) started on 2021-04-08.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.